Bone marrow stromal cells are potentially useful for tendon repair and regeneration. To provide lasting benefits, the seeded cells must survive implantation at local tendon sites. Our objective was to determine the in vivo fate of allogeneic bone marrow stromal cells (bMSCs) at different time points after implantation into patella tendon defects (i.e., at 2, 3, 5, and 8 weeks). The protocol involved the labeling of bMSCs with green fluorescent protein (GFP) or carboxyfluorescein diacetate (CFDA) before implantation. A window defect (5 × 5 mm) was created at the central portion of rabbit patella tendon and subsequently treated with GFP-or CFDA-marked bMSCs. The marked bMSCs were loaded into the window defect with fibrin glue. Upon sacrifice of the rabbits at the different time points, the implant site of the patellar tendon was immediately retrieved and the viability of the labeled cells was assessed under confocal microscopy. The results showed that the seeded bMSCs remained viable within the tendon wound site for at least 8 weeks after implantation. The cell morphology was changed from a round shape at 2 weeks to a spindle shape at 5 weeks after implantation. This study demonstrated that the bMSCs remained viable for prolonged periods after implantation and therefore have the potential to influence the formation and remodeling of neotendon tissue after tendon repair.
INTRODUCTION
In comparison to the use of autologous cells, using allogeneic cells has various commercial and regulatory Bone marrow stromal cells are often referred to as advantages, including the ability: 1) to provide a readymesenchymal stem cells (MSCs) or mesenchymal proto-use implantable biological device; 2) to produce large genitor cells (MPCs). The difference in terminology is cell bank inventories necessary for quality control and because they are derived from separate pluripotent cells safety testing; and 3) to manufacture a reproducible and in the bone marrow (11, 20) . As such, the variation in reliable product. Of course, the use of allogeneic cells names is based on the different isolation protocols. may give rise to the possibility of immune response. How-However, very recent data showed that the human bone ever, this paradigm regarding allogeneic cell-initiated immarrow-derived stem cells cultured in adherent monomune rejection is changing. In the living skin construct, layer are virtually indistinguishable, both physically and such as the commercial product "Apligraf" (4, 21) , studfunctionally, regardless of the method of isolation (13) .
ies have shown that the allogeneic cells seeded did not These bone marrow-derived cells gave rise to the proelicit an immune response in patients. This finding suggenitors of various structural and connective tissues, ingests that certain allogeneic cell types can be used to cluding bone, cartilage, fat, tendon, and muscle (7,10, manufacture engineered tissue without the intervention 16,18). Altman et al. (1) reported that in vitro mechaniof immunosuppression or immunomodulation, which has cal stimulation induces the differentiation of mesenchypositive implications in the use of multipotent cells from mal progenitor cells from the bone marrow into a tenallogenic donors. Devine et al. (6) recently reported the don/ligament cell lineage. For in vivo studies, Young et infusion of allogeneic MSCs in primates. They observed al. (24) and Awad et al. (2) implanted the autologous that it did not cause an immunogenic response. All of bone marrow-derived MSCs for tendon repair in a rabbit these results implicated the possibility of using allogemodel. It was found that MSCs-treated tendon had better neic MSCs for tissue engineering, including tendon tisstructural and biomechanical properties. sue engineering. Our previous studies (14,15) showed 650 OUYANG, GOH, AND LEE that allogeneic bMSCs can accelerate and improve the sone, and ascorbic acid. Von Kossa staining was carried out to detect calcium accumulation. structure and strength of tendon healing in a rabbit Achilles tendon repair model. However, to the best of Animal Model the authors' knowledge, the fate and survivability of al-Fourteen adult female NZW rabbits (weight 2.0-2.5 logeneic bMSCs following local delivery to tendon site kg) were used. The rabbits were anesthetized and the has not been reported in the literature.
right knees shaved and prepped with an iodine scrub The objective of this study was to demonstrate whether solution and alcohol. The right patellar tendons were exallogeneic bone marrow stromal cells (bMSCs) survive posed through 6-8-cm longitudinal incisions. Full thickto be seed cells following implantation into the patellar ness window defects (5 × 5 mm) were excised in the tendon defect site.
central part of each patellar tendon. The corners of each MATERIALS AND METHODS defect were marked with green suture to help identify the wound site at the time of sacrifice and dissection. The protocol involved the isolation and culture of the Six patellar tendon defects (classified as group I) were bMSCs, followed by the labeling of the cells before imtreated with CFDA-labeled allogeneic bMSCs with a plantation in a window defect created in the rabbit padensity of 5 × 10 6 cells in 0.2 ml fibrin gel. Four tendon tella tendon. The following sections give detailed dedefects (classified as group II) were treated with GFPscriptions of the experimental as well as the assessment marked allogeneic bMSCs with a density of about 1 × processes. 10 6 positive cells in 0.2 ml fibrin gel. Finally, four ten-Isolation and Culture of bMSCs don defects (classified as group III) were treated with 0.2 ml fibrin gel alone (see Fig. 1a , b). The epitendon bMSCs were isolated by short-term adherence to was then closed over the defect to cover and maintain plastic as described by Beresford et al. (5) . Following the bMSCs/fibrin gel implant. The skin was then closed the administration of anesthetic, bone marrow was aswith interrupted sutures. Two specimens from the CFDA pirated from the iliac crest of five adult female NZW group (group I) were harvested at 2, 4, and 8 weeks rabbits (weight 2.0-2.5 kg), and collected into polypropostoperation. Two specimens from the GFP group pylene tubes containing 1000 U/ml preservative-free (group II) and the control group (group III) were harheparin. The bone marrow and heparin were well mixed.
vested at 3 and 8 weeks. Immediately after retrieval of Nucleated cells were isolated by density gradient centrifthe implant, the viability of the labeled seeded bMSCs ugation over Ficoll/Paque (Pharmacia). Following this, was assessed using confocal microscopy. the nucleated cell layers were carefully removed and resuspended in culture medium containing DMEM (Gibco), Cell Labeling and Detection 15% (w/v) fetal bovine serum (Hyclone), 100 U/ml pen-CFDA and GFP gene are well recognized as cell icillin, and 100 µg/ml streptocycin (Gibco). The nucletrace markers. Therefore, in this study these two techated cells were plated at the density of 5 million nucleniques were used to investigate the survivability of imated cells per 100-mm dish and incubated at 37°C with planted bMSCs at patellar tendon repair site. For CFDA 5% humidified CO 2 . After 24 h, nonadherent cells were labeling, bMSCs were plated at 80-90% confluence on discarded and adherent cells were cultured. Medium was the first day, then incubated for 20 min (25 µM CFDA) changed every 3 days. When the cells became nearly on the second day. For GFP gene transfection, bMSCs confluent after about 14 days, cells were detached and were plated at 80% confluence on day 1 and then incuserially subcultured. The second-passage cells were used bated for 1 h (GFP plasmid and Transfast reagent) on for osteogenesis and adipogenesis induction. day 2. The positive cells were observed under fluorescent microscopy.
bMSCs Differentiation Assay
To characterize the pluripotential of bone marrow Tissue Preparation for Confocal stromal cells, a number of in vitro experiments were Microscopy Observation carried out. These were differentiation assays to induce Tissue was trimmed to approximately 5 × 5 × 5 mm formation of adipocytes, chondrocytes, and osteoblasts. and blocked. The tissue was then sectioned at 4-10 µm Using the protocol described by Pittenger et al. (17), thickness. The sections were immediately fixed in aceadipogenic differention was induced in the expanded tone at room temperature for 30 s. Then the slides were MSC cultures by treatment with 1-methyl-3-isobutylwashed in PBS and observed under confocal microscopy. xanthine, dexamethasone, insulin, and indomethacin. In-RESULTS duction was detected by oil red staining for lipid vacuoles. Osteogenic differentiation of MSCs was induced
The osteogenic differentiation assays showed that most of the cells had calcium deposit with Von Kossa under the influence of β-glycerol phosphate, dexametha- staining after 2 weeks induction while the control cells All the specimens treated with CFDA showed a lot of viable bMSCs, as indicated by green fluorescence after 2 treated with common medium were negative ( Fig. 2a , b). It was also observed that the cells were committed weeks. About 65-80% of the cells in repair tissues were labeled cells. The cell morphology at this time was to adipogenic differentiation. This was evident through the accumulation of lipid vacuoles after 3 times of in-nearly round (Fig. 3a ). Under transmission microscopy ( Fig. 3b) , the cells were presented as pin dots; there was duction in 2 weeks ( Fig. 2c, d) .
The bMSCs were successfully labeled with CFDA no fiber structure in the matrix at this early time point. After 5 weeks in vivo, the viable cells exhibited good fluorescence (Molecular Probes) in vitro. Twenty-four hours after the CFDA labeling, almost all of the cells orientation and over 90% of the labeled cells changed into tenocyte-like spindle shape (Fig. 3c ), but only about exhibited the green fluorescence. When using the green fluorescence protein (GFP) gene transfection method, 30% of the cells in the repair tendon were labeled cells. Parallel fiber structure was observed in the matrix of only about 10% of the bMSCs expressed the GFP after 48 h. Although the rate was relatively low, the results repair tendon under transmission microscopy (Fig. 3d ). After 8 weeks in vivo, all of the labeled cells exhibited showed that bMSCs can express the marker gene.
All of the defect sites healed well. No gross adverse spindle shape; the number of labeled cells decreased drastically and made up less than 10% of the whole cell response was observed during the entire observation period of 8 weeks. The in vivo cell survivability results population in the repair tendon (Fig. 3e ). Furthermore, the cells had become more spindle shaped and the ma-are as shown in Figure 3 and Figure 4 . Viable cells were observed at the implantation sites (i.e., patella tendon trix denser. The structure of the repaired tendon was similar to that of normal tendon (Fig. 3f ). window defect). As observed, more viable cells were present in the specimens implanted with CFDA-labeled
The group treated with GFP-labeled cells confirmed the results of CFDA trace study (Fig. 4a, b ). Three bMSCs than those in the specimens implanted with GFP-marked bMSCs. This was because of the low effi-weeks after implantation into the patellar tendon window defect, a large amount of labeled cells could be ciency of GFP transfection that resulted in the lower initial density of the implanted GFP-labeled cells. But the traced in the defect site and the cells exhibited a round shape. Eight weeks after implantation, the cell number in vivo data of GFP-labeled cells exhibited the possibility of using bMSCs as gene delivery vehicle.
decreased; however, the cells were well organized along the axis of the tendon. The cell morphology changed tuted by collagen matrix. Moreover, the morphology of bMSCs changed from a round shape to tenocyte-like from round to spindle shaped. These results demonstrated that the bMSCs could survive and differentiate spindle shape 5 weeks after implantation and was maintained even after 8 weeks. These results illustrated that after local delivery.
As expected, a fluorescence signal, which is indica-allogeneic bMSCs were able to survive at the tendon wound site after local delivery. The finding from this tive of labeled implanted cells, was not observed in the normal host tendon (Fig. 5a, b) . study is consistent with a previous observation made by Watanabe et al. (22) . They transplanted bMSCs of transgenic rats to the mid-substance of the medial collateral DISCUSSION ligaments of wild-type rats and found that the trans-The Fate of bMSCs After Implantation planted cells survived after 3 and 7 days at the healing Into Tendon Defects site. However, they only carried out short-term observations, and the phenotype of the cells was not investi-The results of bMSC differentiation assays in vitro suggested that the bMSCs used in this study possessed gated. It should be noted that besides cell survivability, the phenotypic change is another major concern in the pluripotential characteristics and could differentiate into progenitor cells of bone and fat, which is consistent with use of bMSCs in tissue engineering application. The changes in morphology of the bMSCs from round to previous studies (16, 17) . However, the fate of the implanted cells is a prerequisite question that needs to be tenocyte-like spindle shape at 5 weeks and 8 weeks after implantation suggest that bMSCs can differentiate into answered before any tissue engineering applications can be made. Therefore, clear evidence for the sustained in-tenocyte-like cells. However, the lack of specific cell surface marker for tenocytes inhibited the identification tegration in the target tissue of differentiated cells of donor origin must be provided. We examined the fate of of the labeled spindle-shaped cells in this study. Further study is warranted to isolate the labeled cells and then allogeneic bMSCs delivered by fibrin gel and implanted into patella tendon defects. It was found that the im-detect the transcription of tendon phenotype-related genes, such as those encoding scleraxis, Six1, EphA4, planted bMSCs remained viable at least 8 weeks after surgery. But the labeled cell number decreased with and collagen type I. Although few trace studies are available on the fate time. This might have been due to the remodeling process of the repair tendon in which the cells are substi-of locally implanted bMSCs, there is a report that bone marrow-derived adherent mesenchymal cells could sur-recognition (23). Bartholomew et al. (3) found that baboon MSCs failed to elicit a proliferative response from vive and differentiate into various kinds of tissue after systemic infusion (8). With incorporation of those previ-allogeneic lymphocytes. MSCs added into a mixed lymphocyte reaction led to a greater than 50% reduction in ous investigations, the present study suggests that the application of foreign bone marrow stromal cells for in the lymphocyte proliferation. Our in-house data also showed that allogeneic rabbit bMSCs failed to initiate T-situ tissue engineering is reasonable; moreover, bMSCs could be useful as progenitor cells for neotendon for-cell proliferation. These immunoregulatory features may prove useful in future applications of bMSCs for tissue mation.
regeneration and repair. Of course, the as-yet-unknown The Possibility of Allogeneic bMSCs mechanism warrants further research into the transplant for Tissue Engineering immunology of MSCs. Further study in this area will provide fundamental understanding in the use of alloge-Allogeneic cells rather than autologous cells present neic MSCs in tissue engineering. various commercial advantages. In this study, it was observed that allogeneic bMSCs were viable for at least 8
The Potential of bMSCs for Gene Delivery weeks after implantation. Moreover, the bMSCs were in Tendon Repair capable of differentiating into tenocyte-like cells. Similar observations had been reported; for instance, Devine
In this study, bMSCs not only survived but also expressed the green fluorescence protein gene as long as 8 et al. (6) reported an in vivo study which showed that allogeneic MSCs could home into the bone marrow in a weeks after implantation into tendon defect. This result correlated well with previous studies; for example, MHC-unmatched baboon model. Even human MSCs were able to engraft and demonstrated site-specific dif- Zhang et al. (25) conducted an in vitro study to investigate the expression of several transgenes in MSCs fol-ferentiation in fetal sheep with immunologic competence (12). The biotechnology company, Osiris, has used lowing HIV-1 lentiviral vector-mediated gene transfer. They reported that transgene expression was maintained allogeneic baboon MSCs for bone gap repair and medial meniscus regeneration (19). The mechanism for such a in culture for at least 5 months. Gazit et al. (9) performed an in vivo study and found that BMP-2 gene response is not clearly understood. However, it has been shown that human MSCs express class I human leuko-engineered mesenchymal progenitor cells significantly enhanced mouse radial segmental defect repair, suggest-cyte antigen but not class II, which may limit immune ing that the use of mesenchymal stem cell-based gene Caplan, A. I. The dynamic in vivo distribution of bone therapy strategies was promising for the treatment of marrow-derived mesenchymal stem cells after infusion.
bone lesions as well as other tissue repair. It was recog-Cells Tissues Organs 169 (1):12-20; 2001. nized that using cells as gene carrier eliminates the limi- to be noted that the low efficiency of nonvirus gene progenitor cells (mesenchymal progenitor cells): Implications for therapeutic use. Bone Marrow Transplant. 16 (4): transfection on primary bMSCs may limit the clinical 557-564; 1995. progress of using bMSCs for gene therapy. 
